Download PDF

1. Company Snapshot

1.a. Company Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally.The company operates through three segments: Oncology, Diagnostics, and RNA interference.It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.


The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors.In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression.The company was incorporated in 1986 and is based in Madrid, Spain.

Show Full description

1.b. Last Insights on PHM

Pharma Mar's recent performance was negatively impacted by the company's inability to capitalize on its strong fundamentals, despite being undervalued. The absence of recent positive news and the company's lack of innovation in its product offerings have contributed to its underperformance. Additionally, the company's high insider ownership, which was previously seen as a positive, has not translated into significant earnings growth, with estimates suggesting up to 52% earnings growth. The company's recent earnings release has not been made public, but the current market environment, characterized by escalating global trade tensions and economic fluctuations, has likely had a negative impact on the company's performance.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

European Growth Companies With High Insider Ownership December 2025

Dec -04

Source:

Card image cap

High Growth Tech Stocks Including Hacksaw With Potential For Expansion

Dec -04

Source:

Card image cap

High Insider Ownership Growth Companies In Global December 2025

Dec -04

Source:

Card image cap

European Growth Companies With High Insider Ownership In December 2025

Dec -04

Source:

Card image cap

High Growth Tech Stocks With Promising Potential In Global Markets

Dec -03

Source:

Card image cap

Discover 3 Global Growth Companies With Up To 27% Insider Ownership

Dec -03

Source:

Card image cap

European Growth Companies With High Insider Ownership

Dec -03

Source:

Card image cap

European Growth Stocks With High Insider Stakes

Dec -02

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.88%)

6. Segments

Oncology

Expected Growth: 10.9%

Strong demand for Oncology treatments, increasing cancer prevalence, and innovative pipeline of Pharma Mar's Yondelis and lurbinectedin drive 10.9% growth. Expanding indications, geographic reach, and strategic partnerships further fuel growth. Additionally, investments in R&D and regulatory approvals for new products contribute to the segment's rapid expansion.

Diagnostics

Expected Growth: 8.32%

Pharma Mar's diagnostics segment growth of 8.32% is driven by increasing demand for personalized medicine, advancements in genomics and proteomics, and rising adoption of precision medicine. Additionally, growing incidence of chronic diseases, aging population, and expansion into new markets contribute to the segment's growth.

RNAi

Expected Growth: 10.5%

RNAi from Pharma Mar, S.A. growth driven by increasing adoption in oncology and rare genetic disorders, strong pipeline of novel RNAi therapeutics, and strategic partnerships for commercialization. Additionally, growing demand for targeted therapies and increasing investment in RNAi research contribute to the 10.5% growth rate.

7. Detailed Products

Yondelis

Yondelis is a chemotherapy medication used to treat soft tissue sarcoma and ovarian cancer.

Zepzelca

Zepzelca is a chemotherapy medication used to treat metastatic soft tissue sarcoma and liposarcoma.

Aplidin

Aplidin is a chemotherapy medication used to treat multiple myeloma.

Trabectedin

Trabectedin is a chemotherapy medication used to treat soft tissue sarcoma and ovarian cancer.

8. Pharma Mar, S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Pharma Mar, S.A. faces moderate threat from substitutes due to the presence of alternative treatments and therapies for cancer and other diseases.

Bargaining Power Of Customers

Pharma Mar, S.A. has a diverse customer base, and individual customers do not have significant bargaining power.

Bargaining Power Of Suppliers

Pharma Mar, S.A. relies on a few key suppliers for raw materials and equipment, giving them some bargaining power.

Threat Of New Entrants

The pharmaceutical industry is highly competitive, and new entrants can easily disrupt the market with innovative products and technologies.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players and new entrants vying for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 17.68%
Debt Cost 3.95%
Equity Weight 82.32%
Equity Cost 3.51%
WACC 3.59%
Leverage 21.47%

11. Quality Control: Pharma Mar, S.A. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Gubra

A-Score: 4.5/10

Value: 6.8

Growth: 2.4

Quality: 9.9

Yield: 5.0

Momentum: 2.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
ProQR Therapeutics

A-Score: 4.2/10

Value: 6.4

Growth: 6.6

Quality: 4.1

Yield: 0.0

Momentum: 7.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Atai Life Sciences

A-Score: 4.0/10

Value: 6.0

Growth: 2.9

Quality: 5.0

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Pharma Mar

A-Score: 3.6/10

Value: 1.1

Growth: 4.4

Quality: 7.8

Yield: 1.2

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
LAVA Therapeutics

A-Score: 3.3/10

Value: 6.8

Growth: 5.6

Quality: 3.0

Yield: 0.0

Momentum: 3.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
BioArctic

A-Score: 3.2/10

Value: 1.5

Growth: 2.6

Quality: 9.9

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

75.5$

Current Price

75.5$

Potential

-0.00%

Expected Cash-Flows